Ananda Pharma Plc (AQSE:ANA, OTCQB:ANANF) co-founder and CEO Melissa Sturgess talked with Proactive's Stephen Gunnion about the company’s progress towards beginning its first clinical trial in Australia for its cannabinoid-based drug candidate.
Sturgess confirmed that the drug development stage is now complete, allowing the company to move into trials involving healthy volunteers. The trial will compare the pharmacokinetic profile of Ananda’s candidate with Epidiolex, the only CBD drug currently approved by regulators.
Sturgess discussed the recent appointments of Giles Moss and Chris Tovey—both former senior executives at GW Pharmaceuticals, the company behind Epidiolex—as strategic moves to strengthen Ananda’s commercial and regulatory capabilities as it enters the clinical phase.
The Australian Therapeutic Goods Administration has acknowledged Ananda’s first trial. Sturgess noted that Australia offers both strong tax incentives and compatibility with US FDA requirements, helping the company advance its program cost-effectively while also preparing for potential regulatory pathways in the United States.
Each step forward, Sturgess said, brings Ananda closer to dosing its first volunteers in what she described as a critical phase of development.
For more updates, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and enable notifications for future content.
#AnandaPharma #CBDClinicalTrial #MelissaSturgess #CannabinoidResearch #PharmaNews #BiotechUpdate #DrugDevelopment #Epidiolex #AustraliaTrials #FDAPathway